Clinical trial
A Study of rhGAA in Patients With Late-Onset Pompe Disease
NCT00250939 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00250939 |
|---|---|
| Title | A Study of rhGAA in Patients With Late-Onset Pompe Disease |
| Official title | Single-center, Open-label Study of Safety, Pharmacokinetics and Efficacy of rhGAA in Patients With Late-Onset Pompe Disease |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II), Acid Maltase Deficiency Disease, Glycogenosis 2 |
| Intervention type | Biological |
| Interventions | Myozyme |
| Enrollment | 5 |
| Start date | Feb 1, 2005 |
| Primary completion | Jul 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Nov 9, 2005 |
| Last update posted | Feb 6, 2014 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: